Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free NKGN Stock Alerts

NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.06 0.00 (0.00%)
As of 05/22/2026 03:44 PM Eastern
Compare

NKGN vs. RNTX, SKYE, PLRZ, LSTA, and KYNB

Should you buy NKGen Biotech stock or one of its competitors? MarketBeat compares NKGen Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NKGen Biotech include Rein Therapeutics (RNTX), Skye Bioscience (SKYE), Polyrizon (PLRZ), Lisata Therapeutics (LSTA), and Kyntra Bio (KYNB). These companies are all part of the "pharmaceutical products" industry.

How does NKGen Biotech compare to Rein Therapeutics?

NKGen Biotech (NYSE:NKGN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

NKGen Biotech's return on equity of 0.00% beat Rein Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Rein Therapeutics N/A -510.35%-68.14%

Rein Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 676.70%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, NKGen Biotech had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for Rein Therapeutics. NKGen Biotech's average media sentiment score of 0.72 beat Rein Therapeutics' score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.

Company Overall Sentiment
NKGen Biotech Positive
Rein Therapeutics Neutral

NKGen Biotech has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

Rein Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.51N/A
Rein TherapeuticsN/AN/A-$49.87M-$1.90N/A

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rein Therapeutics beats NKGen Biotech on 7 of the 13 factors compared between the two stocks.

How does NKGen Biotech compare to Skye Bioscience?

NKGen Biotech (NYSE:NKGN) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Skye Bioscience had 7 more articles in the media than NKGen Biotech. MarketBeat recorded 9 mentions for Skye Bioscience and 2 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 0.72 beat Skye Bioscience's score of 0.70 indicating that NKGen Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NKGen Biotech
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Skye Bioscience
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Skye Bioscience is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.51N/A
Skye BioscienceN/AN/A-$55.92M-$1.44N/A

NKGen Biotech has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, indicating that its share price is 203% more volatile than the broader market.

NKGen Biotech's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Skye Bioscience N/A -217.27%-162.39%

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,081.72%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Skye Bioscience
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Summary

Skye Bioscience beats NKGen Biotech on 9 of the 14 factors compared between the two stocks.

How does NKGen Biotech compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Company Net Margins Return on Equity Return on Assets
PolyrizonN/A N/A N/A
NKGen Biotech N/A N/A -479.36%

In the previous week, NKGen Biotech had 2 more articles in the media than Polyrizon. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for Polyrizon. NKGen Biotech's average media sentiment score of 0.72 beat Polyrizon's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Polyrizon Neutral
NKGen Biotech Positive

76.2% of NKGen Biotech shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyrizonN/AN/A-$3.34MN/AN/A
NKGen BiotechN/AN/A-$82.94M-$1.51N/A

Polyrizon has a beta of -2.04, indicating that its stock price is 304% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

NKGen Biotech beats Polyrizon on 5 of the 8 factors compared between the two stocks.

How does NKGen Biotech compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 377.71%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 2 articles in the media. Lisata Therapeutics' average media sentiment score of 1.55 beat NKGen Biotech's score of 0.72 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lisata Therapeutics Very Positive
NKGen Biotech Positive

NKGen Biotech's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -103.54% -83.08%
NKGen Biotech N/A N/A -479.36%

Lisata Therapeutics has higher revenue and earnings than NKGen Biotech. Lisata Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K168.27-$16.59M-$1.86N/A
NKGen BiotechN/AN/A-$82.94M-$1.51N/A

Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

Lisata Therapeutics beats NKGen Biotech on 7 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to Kyntra Bio?

NKGen Biotech (NYSE:NKGN) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Kyntra Bio has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.51N/A
Kyntra Bio$6.44M4.40$183.45M$40.460.17

In the previous week, NKGen Biotech had 2 more articles in the media than Kyntra Bio. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for Kyntra Bio. NKGen Biotech's average media sentiment score of 0.72 beat Kyntra Bio's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.

Company Overall Sentiment
NKGen Biotech Positive
Kyntra Bio Neutral

Kyntra Bio has a net margin of 2,199.13% compared to NKGen Biotech's net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Kyntra Bio 2,199.13%N/A -36.71%

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 2.0% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NKGen Biotech has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

Summary

Kyntra Bio beats NKGen Biotech on 9 of the 13 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

Export
MetricNKGen BiotechBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$7.84M$309.61M$6.46B$23.20B
Dividend YieldN/AN/A2.76%4.10%
P/E Ratio-0.01N/A21.2230.65
Price / SalesN/A189.70562.2824.50
Price / CashN/A22.4443.4925.12
Price / Book-0.024.7710.314.74
Net Income-$82.94M-$132.96M$3.57B$1.07B
7 Day PerformanceN/A2.45%6.43%2.36%
1 Month PerformanceN/A31.23%3.57%1.58%
1 Year PerformanceN/A77.59%34.07%28.42%

NKGen Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.06
flat		N/A-79.3%$7.84MN/AN/AN/A
RNTX
Rein Therapeutics
2.5415 of 5 stars		$1.05
-7.5%		$8.00
+665.6%		-49.8%$29.30MN/AN/A9
SKYE
Skye Bioscience
2.7972 of 5 stars		$0.83
-4.5%		$9.80
+1,077.9%		-56.4%$29.24MN/AN/A11
PLRZ
Polyrizon
0.5864 of 5 stars		$15.50
+3.2%		N/A+199.2%$28.99MN/AN/AN/A
LSTA
Lisata Therapeutics
2.2384 of 5 stars		$3.18
+3.1%		$15.00
+372.1%		+18.9%$28.94M$170KN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel